Acute cholangitis is diagnosed on the basis of the clinical features, supported by laboratory evidence of systemic infection. Imaging is helpful in revealing biliary obstruction and any underlying ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. In this phase 3, ...

The survey of European hepatologists demonstrates the lack of clarity in guidelines. A new survey of European health care centers with expertise in managing primary sclerosing cholangitis (PSC) ...

Chemomab Therapeutics has announced that it has successfully completed its End-of-Phase 2 meeting with the FDA, aligning on the design of a single Phase 3 trial for its lead product candidate, ...